ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9
The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...
Nature8d
CRISPR-Cas9 genome editing articles from across Nature Portfolio
CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the ...
Buy Rating for Crispr Therapeutics AG: Strong Pipeline, Strategic Partnerships, and Financial Stability Drive Confidence
Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...